BrainsWay (NASDAQ:BWAY – Get Free Report) is expected to be posting its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect BrainsWay to post earnings of $0.03 per share and revenue of $10.89 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.
BrainsWay Price Performance
Shares of BrainsWay stock opened at $9.41 on Monday. BrainsWay has a 1 year low of $4.61 and a 1 year high of $11.79. The company has a market capitalization of $177.16 million, a P/E ratio of 94.11 and a beta of 1.29. The business has a 50 day moving average price of $10.21 and a 200 day moving average price of $9.56.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of BrainsWay in a report on Monday, December 23rd.
About BrainsWay
BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.
Read More
- Five stocks we like better than BrainsWay
- Why Invest in High-Yield Dividend Stocks?
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- What is the S&P/TSX Index?
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- 3 Monster Growth Stocks to Buy Now
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.
